1238eTiP Phase I/IIa, open-label, dose finding, safety and exploratory trial of THEO-260: A novel oncolytic immunotherapy, by intravenous delivery in patients with high grade serous or endometrioid ovarian cancer
Mariangela Saggese(Theolytics (United Kingdom)), Jonathan Krell(Imperial College London), Douglas Cartwright(Beatson West of Scotland Cancer Centre), Mohammed Zameer(University of Oxford), Matilda Duffy(Theolytics (United Kingdom)), Alexander K. Smith(University of California, San Francisco), M. Bazan Peregrino(Theolytics (United Kingdom)), Sarah P. Blagden(Churchill Hospital), P. Roxburgh(Beatson West of Scotland Cancer Centre), Mark P. Lythgoe(Hammersmith Hospital), R. Ackerman-Johnson(Theolytics (United Kingdom)), David Apelian(Theolytics (United Kingdom)), K. Fisher(Theolytics (United Kingdom)), Rakesh Dattani(Theolytics (United Kingdom))
Cited by 1
Related Papers
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268
Performance status score: do patients and their oncologists agree?
|British Journal of Cancer|2003|222